Tumor-associated Peptides Binding Promiscuously to Human Leukocyte Antigen (HLA) Class II Molecules

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20080206216A1
SERIAL NO

11942394

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
IMMATICS BIOTECHNOLOGIES GMBHPAUL-EHRLICH-STRASSE 15 TUEBINGEN 72076

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dengjel, Jorn Odense, DK 9 352

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation